Journal article
Itaconate as an inflammatory mediator and therapeutic target in cardiovascular medicine
- Abstract:
- Inflammation is a critical component of cardiovascular disease (CVD), encompassing coronary artery disease (CAD), cerebrovascular events and heart failure and is the leading cause of mortality worldwide. In recent years, metabolism has been placed centrally in the governance of the immune response. Termed immunometabolism, immune cells adapt cellular metabolic pathways to meet demands of activation and thus function. This rewiring influences not only the bioenergetics of the cell but altered metabolites act as signalling molecules to regulate cellular response. In this review, we focus on the TCA cycle derivative, itaconate, as one such metabolite with promising immunomodulatory and therapeutic potential in inflammatory cardiovascular disease.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 694.9KB, Terms of use)
-
- Publisher copy:
- 10.1042/BST20210269
Authors
- Publisher:
- Biochemical Society
- Journal:
- Biochemical Society Transactions More from this journal
- Volume:
- 49
- Issue:
- 5
- Pages:
- 2189-2198
- Publication date:
- 2021-10-19
- Acceptance date:
- 2021-09-28
- DOI:
- ISSN:
-
0300-5127
- Language:
-
English
- Keywords:
- Pubs id:
-
1205877
- Local pid:
-
pubs:1205877
- Deposit date:
-
2021-10-27
- ARK identifier:
Terms of use
- Copyright holder:
- Diotallevi et al
- Copyright date:
- 2021
- Rights statement:
- © 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record